Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded Rocket Pharmaceuticals to “Hold” from “Sell.” The broader analyst consensus is also “Hold,” with an average price target of $8.57.
• Rocket shares opened at $3.47, near their 50-day and 200-day moving averages, and have traded between $2.53 and $5.45 over the past year.
• Institutional investors own 98.39% of the company, while insiders have sold 100,498 shares worth $327,220 over the past 90 days; the company reported quarterly EPS of $1.08, exceeding estimates of $0.86.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Monday.

RCKT has been the topic of several other reports. Weiss Ratings lowered Rocket Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Chardan Capital restated a "buy" rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a report on Monday, May 11th. Finally, Wedbush decreased their target price on Rocket Pharmaceuticals from $16.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $8.57.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKT opened at $3.47 on Monday. The company's 50 day simple moving average is $3.38 and its 200 day simple moving average is $3.61. Rocket Pharmaceuticals has a fifty-two week low of $2.53 and a fifty-two week high of $5.45. The firm has a market capitalization of $380.94 million, a P/E ratio of -20.41 and a beta of 0.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.24 and a quick ratio of 9.24.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Monday, August 10th. The biotechnology company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.22. During the same quarter last year, the business posted ($0.62) EPS. On average, analysts predict that Rocket Pharmaceuticals will post -1.4 EPS for the current year.

Insider Transactions at Rocket Pharmaceuticals

In related news, COO Christopher James Stevens sold 36,658 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $3.50, for a total value of $128,303.00. Following the completion of the transaction, the chief operating officer directly owned 505,784 shares in the company, valued at approximately $1,770,244. The trade was a 6.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Gaurav Shah sold 55,684 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total value of $172,063.56. Following the sale, the chief executive officer directly owned 1,061,724 shares of the company's stock, valued at approximately $3,280,727.16. The trade was a 4.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 100,498 shares of company stock worth $327,220. 21.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Several large investors have recently made changes to their positions in RCKT. ADAR1 Capital Management LLC bought a new stake in Rocket Pharmaceuticals in the 2nd quarter valued at $1,489,000. PDT Partners LLC bought a new position in Rocket Pharmaceuticals during the 2nd quarter worth about $638,000. Canada Pension Plan Investment Board bought a new position in Rocket Pharmaceuticals during the 2nd quarter worth about $200,000. Legal & General Group Plc acquired a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter valued at about $31,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter valued at about $91,000. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company's pipeline comprises multiple product candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source